樹状細胞がんワクチンの世界市場レポート 2025年

樹状細胞がんワクチン市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.1％で40億米ドルに成長します。予測期間の成長は、オミックス技術の統合、世界の高齢化、デジタルヘルスソリューションの出現、患者支援活動や啓発キャンペーンの増加、人工知能（AI）の統合、バイオマーカー主導型治療への注力などに起因すると考えられます。予測期間における主な動向としては、再生医療の進展、ドラッグデリバリーシステムの革新、患者中心の医薬品開発、新抗原同定の進展、次世代ワクチンプラットフォームの開発などが挙げられます。

樹状細胞がんワクチン市場は、がん罹患率の増加によって成長する態勢が整っています。異常細胞の無秩序な増殖を特徴とするがんは、ライフスタイルの選択、環境要因、遺伝的素因など様々な要因に影響されます。樹状細胞がんワクチンは、がん細胞を標的として身体の免疫システムを活性化することで、がん治療において重要な役割を果たし、患者の転帰改善につながる可能性があります。例えば、世界保健機関（WHO）の予測では、2050年までにがん患者が大幅に増加するとされており、この増大する医療課題に対処するために樹状細胞がんワクチンのような革新的治療が緊急に必要であることが強調されています。

樹状細胞がんワクチン市場の主なプレーヤーは、治療効果の高いがんワクチンの開発を進め、患者の臨床治療を強化するために、戦略的パートナーシップの形成に積極的に取り組んでいます。相互の事業目標の達成を目的としたこれらの提携は、ワクチン開発を加速させるための資源や専門知識の融合を促進します。例えば、ウォルター・アンド・イライザ・ホール医学研究所は、ピーター・マッカラムがんセンターと提携し、治療選択肢が限られている患者を対象としたがんワクチン開発のために多額の資金援助を受けています。この共同研究は、30年前に行われた先駆的な調査に基づいており、がん患者のための画期的な臨床試験を開始する可能性を秘めています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ禍、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界樹状細胞がんワクチンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の樹状細胞がんワクチン市場：成長率分析
• 世界の樹状細胞がんワクチン市場の実績：規模と成長, 2019-2024
• 世界の樹状細胞がんワクチン市場の予測：規模と成長, 2024-2029, 2034F
• 世界樹状細胞がんワクチン総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の樹状細胞がんワクチン市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クレアバックス
• シプロイセルT（プロベンジ）
• その他の製品
• 世界の樹状細胞がんワクチン市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• がんセンター
• 外来手術センター
• クリニック
• 世界の樹状細胞がんワクチン市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 小児科
• 大人
• 世界の樹状細胞がんワクチン市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 腫瘍学
• 調査機関
• バイオ医薬品企業
• 世界の樹状細胞がんワクチン市場Creavaxのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 臨床試験におけるCreavax
• クリーバックスの商業化
• 世界の樹状細胞がんワクチン市場シプロイセルT（プロベンジ）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 前立腺がんにおけるシプルイセル-T
• シプリューセルTの市場シェア
• シプロイセルTの規制承認
• 世界の樹状細胞がんワクチン市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• デイバックス
• オンコバックス
• GVAX
• その他の実験的樹状細胞ワクチン

第7章 地域別・国別分析

• 世界の樹状細胞がんワクチン市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の樹状細胞がんワクチン市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 樹状細胞がんワクチン市場：競合情勢
• 樹状細胞がんワクチン市場：企業プロファイル
  • Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • Cognate BioServices Inc. Overview, Products and Services, Strategy and Financial Analysis
  • APAC Biotech Overview, Products and Services, Strategy and Financial Analysis
  • Asterias Biotherapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Batavia Biosciences
• Medigene AG
• Zelluna Immunotherapy AS
• Diakonos Oncology
• Elios Therapeutics LLC
• Northwest Biotherapeutics
• Oncopep Inc.
• PDC*line Pharma SA
• SillaJen Biotherapeutics Inc.
• VLP Therapeutics
• ImmunityBio Inc.
• Celldex Therapeutics Inc.
• Bellicum Pharmaceuticals
• Argos Therapeutics Inc.
• DCPrime

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 樹状細胞がんワクチン市場2029：新たな機会を提供する国
• 樹状細胞がんワクチン市場2029：新たな機会を提供するセグメント
• 樹状細胞がんワクチン市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dendritic cell cancer vaccines are immunotherapies that leverage the body's dendritic cells to stimulate an immune response against cancer cells, potentially enhancing the body's ability to recognize and destroy tumors. They represent a personalized treatment approach tailored to target specific types of cancer, aiming to bolster the immune system's capacity to combat the disease. By harnessing the body's immune system, dendritic cell cancer vaccines hold promise for eliciting more effective and durable responses in patients.

The main products in the realm of dendritic cell cancer vaccines include CreaVax, Sipuleucel-T (Provenge), and others. CreaVax is a dendritic cell cancer vaccine crafted to activate the body's immune response against cancer cells, employing specialized immune cells loaded with tumor-specific antigens. These products are typically distributed through hospitals, cancer centers, ambulatory surgical centers, and clinics, with applications extending to both pediatric and adult populations. End users encompass oncology practitioners, research institutions, and biopharmaceutical companies alike.

The dendritic cell cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides dendritic cell cancer vaccine market statistics, including the dendritic cell cancer vaccine industry global market size, regional shares, competitors with the dendritic cell cancer vaccine market share, detailed dendritic cell cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the dendritic cell cancer vaccine industry. These dendritic cell cancer vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dendritic cell cancer vaccine market size has grown rapidly in recent years. It will grow from $2.46 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to cancer awareness initiatives, investments in manufacturing infrastructure, exploration of combination therapies, adoption of precision medicine, and improved understanding of the immune system.

The dendritic cell cancer vaccine market size is expected to see rapid growth in the next few years. It will grow to $4 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to integration of omics technologies, global aging population, emergence of digital health solutions, increasing patient advocacy efforts and awareness campaigns, integration of artificial intelligence (ai), focus on biomarker-driven therapies. Major trends in the forecast period include regenerative medicine advances, innovations in vaccine delivery systems, patient-centric drug development, advances in neoantigen identification, development of next-generation vaccine platforms.

The dendritic cell cancer vaccine market is poised for growth driven by the increasing incidence of cancer cases. Cancer, characterized by the uncontrolled proliferation of abnormal cells, is influenced by various factors including lifestyle choices, environmental factors, and genetic predispositions. Dendritic cell cancer vaccines play a crucial role in cancer treatment by activating the body's immune system to target cancer cells, potentially leading to improved patient outcomes. For example, projections from the World Health Organisation suggest a substantial increase in cancer cases by 2050, highlighting the urgent need for innovative treatments such as dendritic cell cancer vaccines to address this growing healthcare challenge.

Key players in the dendritic cell cancer vaccine market are actively engaged in forming strategic partnerships to advance the development of curative cancer vaccines and enhance clinical care for patients. These collaborations, aimed at achieving mutual business objectives, facilitate the pooling of resources and expertise to accelerate vaccine development. For instance, the Walter and Eliza Hall Institute of Medical Research partnered with the Peter MacCallum Cancer Centre to receive substantial funding for the development of a cancer vaccine targeting patients with limited therapeutic options. This collaboration builds upon pioneering research conducted three decades ago, with the potential to initiate groundbreaking clinical trials for cancer patients.

In March 2021, Charles River Laboratories International Inc. expanded its capabilities by acquiring Cognate BioServices Inc., a leading provider of contract development services for autologous dendritic cell vaccines. This strategic acquisition enables Charles River Laboratories to offer integrated solutions to clients, combining manufacturing with essential analytical testing to streamline processes and accelerate the time-to-market for novel dendritic cell vaccine candidates.

Major companies operating in the dendritic cell cancer vaccine market are Dendreon Pharmaceuticals LLC, Celgene Corporation, Cognate BioServices Inc., APAC Biotech, Asterias Biotherapeutics Inc, Batavia Biosciences, Medigene AG, Zelluna Immunotherapy AS, Diakonos Oncology, Elios Therapeutics LLC, Northwest Biotherapeutics, Oncopep Inc., PDC*line Pharma SA, SillaJen Biotherapeutics Inc., VLP Therapeutics, ImmunityBio Inc., Celldex Therapeutics Inc., Bellicum Pharmaceuticals, Argos Therapeutics Inc., DCPrime, NuGenerex Immuno-Oncology

North America was the largest region in the dendritic cell cancer vaccine market in 2024. The regions covered in the dendritic cell cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dendritic cell cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dendritic cell cancer vaccines market consists of sales of autologous dendritic cell vaccines, allogeneic dendritic cell vaccines, and experimental vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dendritic Cell Cancer Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dendritic cell cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dendritic cell cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dendritic cell cancer vaccine market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: CreaVax; Sipuleucel-T (Provenge); Other Products
• 2) By Distribution Channel: Hospitals; Cancer Centers; Ambulatory Surgical Centers; Clinics
• 3) By Application: Pediatrics; Adults
• 4) By End User: Oncology; Research Institutions; Biopharmaceutical Companies
• Subsegments:
• 1) By Creavax: Creavax In Clinical Trials; Creavax Commercialization
• 2) By Sipuleucel-T (Provenge): Sipuleucel-T In Prostate Cancer; Sipuleucel-T Market Share; Sipuleucel-T Regulatory Approvals
• 3) By Other Products: Dcvax; Oncovax; GVAX; Other Experimental Dendritic Cell Vaccines
• Companies Mentioned: Dendreon Pharmaceuticals LLC; Celgene Corporation; Cognate BioServices Inc.; APAC Biotech; Asterias Biotherapeutics Inc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dendritic Cell Cancer Vaccine market Characteristics

3. Dendritic Cell Cancer Vaccine market Trends And Strategies

4. Dendritic Cell Cancer Vaccine market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Dendritic Cell Cancer Vaccine Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dendritic Cell Cancer Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dendritic Cell Cancer Vaccine market Growth Rate Analysis
• 5.4. Global Dendritic Cell Cancer Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dendritic Cell Cancer Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dendritic Cell Cancer Vaccine Total Addressable Market (TAM)

6. Dendritic Cell Cancer Vaccine market Segmentation

• 6.1. Global Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• CreaVax
• Sipuleucel-T (Provenge)
• Other Products
• 6.2. Global Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Cancer Centers
• Ambulatory Surgical Centers
• Clinics
• 6.3. Global Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pediatrics
• Adults
• 6.4. Global Dendritic Cell Cancer Vaccine market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Research Institutions
• Biopharmaceutical Companies
• 6.5. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Creavax, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Creavax In Clinical Trials
• Creavax Commercialization
• 6.6. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Sipuleucel-T (Provenge), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Sipuleucel-T In Prostate Cancer
• Sipuleucel-T Market Share
• Sipuleucel-T Regulatory Approvals
• 6.7. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dcvax
• Oncovax
• GVAX
• Other Experimental Dendritic Cell Vaccines

7. Dendritic Cell Cancer Vaccine market Regional And Country Analysis

• 7.1. Global Dendritic Cell Cancer Vaccine market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dendritic Cell Cancer Vaccine market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dendritic Cell Cancer Vaccine market

• 8.1. Asia-Pacific Dendritic Cell Cancer Vaccine market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dendritic Cell Cancer Vaccine market

• 9.1. China Dendritic Cell Cancer Vaccine market Overview
• 9.2. China Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dendritic Cell Cancer Vaccine market

• 10.1. India Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dendritic Cell Cancer Vaccine market

• 11.1. Japan Dendritic Cell Cancer Vaccine market Overview
• 11.2. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dendritic Cell Cancer Vaccine market

• 12.1. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dendritic Cell Cancer Vaccine market

• 13.1. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dendritic Cell Cancer Vaccine market

• 14.1. South Korea Dendritic Cell Cancer Vaccine market Overview
• 14.2. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dendritic Cell Cancer Vaccine market

• 15.1. Western Europe Dendritic Cell Cancer Vaccine market Overview
• 15.2. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dendritic Cell Cancer Vaccine market

• 16.1. UK Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dendritic Cell Cancer Vaccine market

• 17.1. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dendritic Cell Cancer Vaccine market

• 18.1. France Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dendritic Cell Cancer Vaccine market

• 19.1. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dendritic Cell Cancer Vaccine market

• 20.1. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dendritic Cell Cancer Vaccine market

• 21.1. Eastern Europe Dendritic Cell Cancer Vaccine market Overview
• 21.2. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dendritic Cell Cancer Vaccine market

• 22.1. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dendritic Cell Cancer Vaccine market

• 23.1. North America Dendritic Cell Cancer Vaccine market Overview
• 23.2. North America Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dendritic Cell Cancer Vaccine market

• 24.1. USA Dendritic Cell Cancer Vaccine market Overview
• 24.2. USA Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dendritic Cell Cancer Vaccine market

• 25.1. Canada Dendritic Cell Cancer Vaccine market Overview
• 25.2. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dendritic Cell Cancer Vaccine market

• 26.1. South America Dendritic Cell Cancer Vaccine market Overview
• 26.2. South America Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dendritic Cell Cancer Vaccine market

• 27.1. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dendritic Cell Cancer Vaccine market

• 28.1. Middle East Dendritic Cell Cancer Vaccine market Overview
• 28.2. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dendritic Cell Cancer Vaccine market

• 29.1. Africa Dendritic Cell Cancer Vaccine market Overview
• 29.2. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dendritic Cell Cancer Vaccine market Competitive Landscape And Company Profiles

• 30.1. Dendritic Cell Cancer Vaccine market Competitive Landscape
• 30.2. Dendritic Cell Cancer Vaccine market Company Profiles
  • 30.2.1. Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Cognate BioServices Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. APAC Biotech Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Asterias Biotherapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Dendritic Cell Cancer Vaccine market Other Major And Innovative Companies

• 31.1. Batavia Biosciences
• 31.2. Medigene AG
• 31.3. Zelluna Immunotherapy AS
• 31.4. Diakonos Oncology
• 31.5. Elios Therapeutics LLC
• 31.6. Northwest Biotherapeutics
• 31.7. Oncopep Inc.
• 31.8. PDC*line Pharma SA
• 31.9. SillaJen Biotherapeutics Inc.
• 31.10. VLP Therapeutics
• 31.11. ImmunityBio Inc.
• 31.12. Celldex Therapeutics Inc.
• 31.13. Bellicum Pharmaceuticals
• 31.14. Argos Therapeutics Inc.
• 31.15. DCPrime

32. Global Dendritic Cell Cancer Vaccine market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dendritic Cell Cancer Vaccine market

34. Recent Developments In The Dendritic Cell Cancer Vaccine market

35. Dendritic Cell Cancer Vaccine market High Potential Countries, Segments and Strategies

• 35.1 Dendritic Cell Cancer Vaccine market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dendritic Cell Cancer Vaccine market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dendritic Cell Cancer Vaccine market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer